Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU)

2.2 Indications The currently approved indications for these agents include: Type 2 diabetes mellitus Overweight and obesity Beyond diabetes and obesity, further indications under investigation for GLP1 RAs include: Osteoarthritis Obstructive sleep apnea Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis 2.3 Benefits and Harms of Continuation/Discontinuation in the Perioperative Period: 2.3.1 Benefits: According to the guidelines, the acute use of these drugs may offer benefits based on published data: Improved perioperative glycemic control Lower postoperative insulin requirements Reduced risk of hypoglycemia These benefits may lead to reduced complications associated with hyperglycemia (such as a shorter hospital stay, fewer surgical site infections, less acute kidney injury, fewer acute coronary syndromes, reduced critical care admissions, and shorter durations on a ventilator) Improved cardiovascular outcomes 2.3.2 Harms There is an increased risk of pulmonary aspiration

In contrast, the protein content increased significantly after protein isolation in comparison to the defatted meals
AOD-9604 primarily targets fat metabolism MOTS-c focuses on mitochondrial function and metabolic efficiency Tesamorelin increases physiologic growth hormone release and reduces visceral fat Semaglutide reduces appetite through GLP-1 signaling Tirzepatide combines GLP-1 and GIP receptor activation and currently delivers some of the most impressive weight-loss results seen in modern medicine Understanding these differences is essential when choosing the right therapy for weight loss, metabolic health, body composition, or long-term wellness goals
They can explore whether there are barriers to adherence that need addressing, such as injection anxiety, side effects, or practical difficulties with the injection device